Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status October 20, 2016Vol.39 No.09
Drugs & Targets Novartis, MEI Pharma. Receive Breakthrough Therapy Designations September 22, 2016Vol.39 No.08
Study Confirms Association Between RFA Burn Time, OS In Patients Receiving ThermoDox September 22, 2016Vol.39 No.08
Two-drug Immunotherapy May Produce Better Survival in Advanced Melanoma September 22, 2016Vol.39 No.08
Abemaciclib Phase III Trial Continues After Interim Efficacy Criteria Not Met September 22, 2016Vol.39 No.08
